PMID- 31213859
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Electronic)
IS  - 1178-6973 (Linking)
VI  - 12
DP  - 2019
TI  - Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and 
      skin structure infections: a systematic review and meta-analysis of randomized 
      controlled trials.
PG  - 1415-1423
LID - 10.2147/IDR.S202160 [doi]
AB  - Purpose: To assess the clinical efficacy and safety of delafloxacin for treating 
      acute bacterial skin and skin structure infections (ABSSSIs) in adult patients. 
      Patients and methods: The Cochrane Library, EBSCO, EMBASE, Ovid Medline, PubMed, 
      and Web of Science databases were searched up to November 2018. Only randomized 
      controlled trials (RCTs) that evaluated delafloxacin and other comparators for 
      the treatment of ABSSSIs were included. The primary outcome was the clinical cure 
      rate and the secondary outcomes were microbiological response and the risk of 
      adverse events. Results: Four RCTs were included. Overall, delafloxacin exhibited 
      a clinical cure rate similar to the rates of the comparator drugs in the 
      treatment of ABSSSI (OR, 1.05; 95% CI, 0.87-1.27, I(2) =16%) and 
      methicillin-resistant Staphylococcus aureus (MRSA)-associated ABSSSI (OR, 1.12; 
      95% CI, 0.71-1.77, I(2) =0%). Delafloxacin had a microbiological eradication 
      (documented and presumed) rate similar to the rates of the comparators in the 
      treatment of ABSSSI (OR, 1.21; 95% CI, 0.58-2.50, I(2) =0%) and MRSA-associated 
      ABSSSIs (OR, 1.16; 95% CI, 0.37-3.60, I(2) =0%). Delafloxacin and the comparators 
      did not differ significantly in the risk of serious adverse events (AEs), 
      treatment-emergent adverse events (TEAEs), and TEAEs related to the study drug. 
      However, the risk of discontinuation of the study drug due to an AE was lower for 
      delafloxacin than for the comparators (OR, 0.33; 95% CI, 0.15-0.74, I(2) =0%). 
      Conclusion: The clinical efficacy of delafloxacin is as high as that of the 
      comparator drugs in the treatment of ABSSSI, including MRSA-associated 
      infections; furthermore, this antibiotic is as well-tolerated as the comparators.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian, People's Republic of China.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian, People's Republic of China.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Department of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan.
FAU - Huang, Hui-Ting
AU  - Huang HT
AD  - Department of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20190527
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
PMC - PMC6549389
OTO - NOTNLM
OT  - MRSA
OT  - acute bacterial skin and skin structure infections
OT  - delafloxacin
OT  - efficacy
OT  - safety
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/20 06:00
MHDA- 2019/06/20 06:01
PMCR- 2019/05/27
CRDT- 2019/06/20 06:00
PHST- 2019/01/19 00:00 [received]
PHST- 2019/05/08 00:00 [accepted]
PHST- 2019/06/20 06:00 [entrez]
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/06/20 06:01 [medline]
PHST- 2019/05/27 00:00 [pmc-release]
AID - 202160 [pii]
AID - 10.2147/IDR.S202160 [doi]
PST - epublish
SO  - Infect Drug Resist. 2019 May 27;12:1415-1423. doi: 10.2147/IDR.S202160. 
      eCollection 2019.